DMPA-SC stock: Cross-site trends by facility type

Magalona, Sophia; Wood, Shannon N.; Makumbi, Frederick; OlaOlorun, Funmilola; Omoluabi, Elizabeth; Pierre, Akilimali; Guiella, Georges; Cover, Jane; Anglewicz, Philip

doi:10.1016/j.conx.2022.100075

Cited by 1 publication

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 27 28 Furthermore, shortages and understocking of DMPA-SC may impact provider willingness to prescribe this method and meet women’s desires regarding self-injection. 31 Nonetheless, given the substantial advocacy and funding resources promoting DMPA-SC as a self-injectable method of contraception, learning more about women’s attitudes towards self-injection and DMPA-SC is critical. Investments in both quantitative and qualitative research must be made to understand women’s preferences for selecting a contraceptive method and hesitancy towards self-injecting.…”

Section: Discussionmentioning

confidence: 99%

“…Demand generation surrounding self-injection and continued training may be important for increasing interest in self-injectable DMPA-SC; of these contexts, to date, only Nigeria has promotional campaigns surrounding self-injection 27 28. Furthermore, shortages and understocking of DMPA-SC may impact provider willingness to prescribe this method and meet women’s desires regarding self-injection 31. Nonetheless, given the substantial advocacy and funding resources promoting DMPA-SC as a self-injectable method of contraception, learning more about women’s attitudes towards self-injection and DMPA-SC is critical.…”

Section: Discussionmentioning

confidence: 99%

“…30 For DMPA-SC use to continue to rise, DMPA-SC should be offered to both non-users of contraception and users of other contraceptive methods, to ensure that women have access to a wide range of methods to use in line with their preferences. While supply constraints may partially explain stagnation, PMA data examining DMPA-SC provision at public and private facilities indicate increasing or stable stock between 2018 and 2020 (with exceptions of private facilities in Burkina Faso and Nigeria-Kano) 31 ; however, decreases in DMPA-SC given the COVID-19 pandemic and global supply chain delays are certainly plausible, and the pandemic’s full impact on contraceptive commodities and usage has not yet been examined.…”

Section: Progress In Dmpa-sc Use Has Been Inconsistent Over Time and ...mentioning

confidence: 99%

See 2 more Smart Citations

Self-injected contraceptives: does the investment reflect women’s preferences?

et al. 2022

Self Cite

View full text Add to dashboard Cite

Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) is an innovative contraceptive method aimed at meeting women’s unique circumstances and needs, largely due to its ability to be self-injected. Substantial research and advocacy investments have been made to promote roll-out of DMPA-SC across sub-Saharan Africa. To date, research on the demand for DMPA-SC as a self-injectable method has been conducted largely with healthcare providers, via qualitative research, or with highly specific subsamples that are not population based. Using three recent rounds of data from Performance Monitoring for Action, we examined population-representative trends in demand, use, and preference for self-injection among current non-users in Burkina Faso, the Democratic Republic of Congo (Kinshasa and Kongo Central regions), Kenya, and Nigeria (Lagos and Kano States). We found that while over 80.0% of women had heard of injectables across settings, few women had heard of self-injection (ranging from 13.0% in Kenya to 24.8% in Burkina Faso). Despite initial increases in DMPA-SC prevalence, DMPA-SC usage began to stagnate or even decrease in all settings in the recent three years (except in Nigeria-Kano). Few (0.0%–16.7%) current DMPA-SC users were self-injecting, and the majority instead were relying on a healthcare provider for administration of DMPA-SC. Among current contraceptive non-users wishing to use an injectable in the future, only 1.5%–11.4% preferred to self-inject. Our results show that self-injection is uncommon, and demand for self-injection is very limited across six settings, calling for further qualitative and quantitative research on women’s views on DMPA-SC and self-injection and, ultimately, their contraceptive preferences and needs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Progress In Dmpa-sc Use Has Been Inconsistent Over Time and ...mentioning

confidence: 99%

See 1 more Smart Citation